芳香烃受体在炎症性皮肤病中的研究进展

doi:10.11958/20240117

天津医药 ›› 2024, Vol. 52 ›› Issue (11): 1221-1225.doi: 10.11958/20240117

芳香烃受体在炎症性皮肤病中的研究进展

刘浩英¹(), 史天威¹^,²^,^△()

1 河南中医药大学第五临床医学院（郑州人民医院）（邮编450000）
2 河南省人民医院（郑州大学人民医院）皮肤科

收稿日期:2024-01-24 修回日期:2024-05-23 出版日期:2024-11-15 发布日期:2024-11-12
通讯作者: △E-mail：stw6666@163.com
作者简介:刘浩英（1996），女，硕士在读，主要从事皮肤疾病基础研究。E-mail：1191546226@qq.com
基金资助:
国家自然科学基金面上项目(81773344);河南省医学科技攻关计划联合共建项目(LHGJ20200685)

Progress of the aryl hydrocarbon receptor in inflammatory skin diseases

LIU Haoying¹(), SHI Tianwei¹^,²^,^△()

1 The Fifth Clinical Medical College of Henan University of Traditional Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou 450000, China
2 Department of Dermatology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital)

Received:2024-01-24 Revised:2024-05-23 Published:2024-11-15 Online:2024-11-12
Contact: △E-mail：stw6666@163.com

刘浩英, 史天威. 芳香烃受体在炎症性皮肤病中的研究进展[J]. 天津医药, 2024, 52(11): 1221-1225.

LIU Haoying, SHI Tianwei. Progress of the aryl hydrocarbon receptor in inflammatory skin diseases[J]. Tianjin Medical Journal, 2024, 52(11): 1221-1225.

摘要/Abstract

摘要：

芳香烃受体（AhR）又名二噁英受体，是一种配体依赖型转录因子。因其在癌症的发生发展中具有重要作用而一直受到广泛关注。AhR已被认为是免疫和炎症反应中宿主-环境相互作用的重要调节剂，参与多种皮肤病的发病机制。由于AhR在所有皮肤细胞类型中高度表达，并调节许多对皮肤基本功能至关重要的基因，其有望成为炎症性皮肤病治疗的新靶向。就AhR与炎症性皮肤疾病相关的研究成果进行阐述和分析，以助力加快新药物的研发。

关键词: 受体, 芳香烃, 炎症, 皮肤疾病

Abstract:

The aryl hydrocarbon receptor (AhR), also known as dioxin receptor, is a ligand-dependent transcription factor. Because of its important role in occurrence and development of cancer, it has been widely studied. AhR is now considered to be an important regulator of host-environment interactions in immune and inflammatory responses and is involved in pathogenesis of many skin diseases. Because AhR is highly expressed in all types of skin cells and regulates many genes that are critical to skin function, it has the potential to be a new target for the treatment of inflammatory skin diseases. This paper presents and analyzes research findings on the relationship between AhR and inflammatory skin diseases to help accelerate the development of new drugs.

Key words: receptors, aryl hydrocarbon, inflammation, skin diseases

中图分类号:

R751

图/表 1

参考文献 46

[1]	OPITZ C A, HOLFELDER P, PRENTZELL M T, et al. The complex biology of aryl hydrocarbon receptor activation in cancer and beyond[J]. Biochem Pharmacol, 2023,216:115798. doi:10.1016/j.bcp.2023.115798.
[2]	GUILLON C, MEZIANI M, ABDELLI S, et al. The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants[J]. Eur J Dermatol, 2022, 32(3):305-311. doi:10.1684/ejd.2022.4262.
[3]	ACCIOLI C, DA S M, SANTOS B, et al. Aryl hydrocarbon receptor as a therapeutical target of environmentally induced skin conditions[J]. Mol Pharmacol, 2023, 103(5):255-265. doi:10.1124/molpharm.122.000627.
[4]	BUNGSU I, KIFLI N, AHMAD S R, et al. Herbal plants:the role of AhR in mediating immunomodulation[J]. Front Immunol, 2021,12:697663. doi:10.3389/fimmu.2021.697663.
[5]	KEAM S J. Tapinarof cream 1%:first approval[J] Drugs, 2022, 82(11):1221-1228. doi:10.1007/s40265-022-01748-6.
[6]	KIM H B, UM J Y, CHUNG B Y, et al. Aryl hydrocarbon receptors:evidence of therapeutic targets in chronic inflammatory skin diseases[J]. Biomedicines, 2022, 10(5):1087. doi:10.3390/biomedicines10051087.
[7]	KOU Z, TRAN F, DAI W. Heavy metals,oxidative stress,and the role of AhR signaling[J]. Toxicol Appl Pharmacol, 2024,482:116769. doi:10.1016/j.taap.2023.116769.
[8]	SAFE S, JIN U H, PARK H, et al. Aryl hydrocarbon receptor (AHR) ligands as selective AHR modulators (SAhRMs)[J]. Int J Mol Sci, 2020, 21(18):6654. doi:10.3390/ijms21186654.
[9]	GRANADOS J C, FALAH K, KOO I, et al. AHR is a master regulator of diverse pathways in endogenous metabolism[J]. Sci Rep, 2022, 12(1):16625. doi:10.1038/s41598-022-20572-2.
[10]	REJANO-GORDILLO C M, MARIN-DIAZ B, ORDIALES-TALAVERO A, et al. From nucleus to organs:insights of aryl hydrocarbon receptor molecular mechanisms[J]. Int J Mol Sci, 2022, 23(23):14919. doi:10.3390/ijms232314919.
[11]	NAPOLITANO M, FABBROCINI G, MARTORA F, et al. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases[J]. Cells, 2021, 10(12):3559. doi:10.3390/cells10123559.
[12]	LIU H M, CHENG M Y, XUN M H, et al. Possible mechanisms of oxidative stress-induced skin cellular senescence,inflammation,and cancer and the therapeutic potential of plant polyphenols[J]. Int J Mol Sci, 2023, 24(4):3755. doi:10.3390/ijms24043755.
[13]	SANTIBANEZ-ANDRADE M, QUEZADA-MALDONADO E M, RIVERA-PINEDA A, et al. The road to malignant cell transformation after particulate matter exposure:from oxidative stress to genotoxicity[J]. Int J Mol Sci, 2023, 24(2):1782. doi:10.3390/ijms24021782.
[14]	VOGELEY C, ROLFES K M, KRUTMANN J, et al. The aryl hydrocarbon receptor in the pathogenesis of environmentally-induced squamous cell carcinomas of the skin[J]. Front Oncol, 2022,12:841721. doi:10.3389/fonc.2022.841721.
[15]	MOKRZYNSKI K, KRZYSZTYNSKA-KULETA O, ZAWROTNIAK M, et al. Fine particulate matter-induced oxidative stress mediated by UVA-visible light leads to keratinocyte damage[J]. Int J Mol Sci, 2021, 22(19):10645. doi:10.3390/ijms221910645.
[16]	CASTANEDA A R, PINKERTON K E, BEIN K J, et al. Ambient particulate matter activates the aryl hydrocarbon receptor in dendritic cells and enhances Th17 polarization[J]. Toxicol Lett, 2018, 292:85-96. doi:10.1016/j.toxlet.2018.04.020.
[17]	PRASAD S N, NAGARKATTI M, NAGARKATTI P. From suppressor T cells to regulatory T cells:how the journey that began with the discovery of the toxic effects of TCDD led to better understanding of the role of AhR in immunoregulation[J]. Int J Mol Sci, 2020, 21(21):7849. doi:10.3390/ijms21217849.
[18]	KIM J, LEE J, LI X, et al. Single-cell transcriptomics suggest distinct upstream drivers of IL-17A/F in hidradenitis versus psoriasis[J]. J Allergy Clin Immunol, 2023, 152(3):656-666. doi:10.1016/j.jaci.2023.05.012.
[19]	DAVID E, CZARNOWICKI T. The pathogenetic role of Th17 immune response in atopic dermatitis[J]. Curr Opin Allergy Clin Immunol, 2023, 23(5):446-453. doi:10.1097/ACI.0000000000000926.
[20]	UBEROI A, BARTOW-MCKENNEY C, ZHENG Q, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor[J]. Cell Host Microbe, 2021, 29(8):1235-1248. doi:10.1016/j.chom.2021.05.011.
[21]	TSUJI G, YAMAMURA K, KAWAMURA K, et al. Novel therapeutic targets for the treatment of atopic dermatitis[J]. Biomedicines, 2023, 11(5):1303. doi:10.3390/biomedicines11051303.
[22]	黎敏, 龚坚, 吴伟伟, 等. Nrf2/HO-1通路在银屑病中作用的研究进展[J]. 天津医药, 2024, 52(5):552-556.
	LI M, GONG J, WU W W, et al. Research progress on the role of Nrf2/HO-1 pathway in psoriasis[J]. Tianjin Med J, 2024, 52(5):552-556. doi:10.11958/20231583.
[23]	JANG Y S, JEONG S, KIM A R, et al. Cannabidiol mediates epidermal terminal differentiation and redox homeostasis through aryl hydrocarbon receptor(AhR)-dependent signaling[J]. J Dermatol Sci, 2023, 109(2):61-70. doi:10.1016/j.jdermsci.2023.01.008.
[24]	UCHI H, YASUMATSU M, MORINO-KOGA S, et al. Inhibition of aryl hydrocarbon receptor signaling and induction of NRF2-mediated antioxidant activity by cinnamaldehyde in human keratinocytes[J]. J Dermatol Sci, 2017, 85(1):36-43. doi:10.1016/j.jdermsci.2016.10.003.
[25]	CHESSA M A, LA PLACA M, PATRIZI A, et al. Chloracne:a case series on cutaneous expression of CYP1A1 as diagnostic biomarker[J]. Clin Exp Dermatol, 2021, 46(5):896-900. doi:10.1111/ced.14617.
[26]	FURUE M, FUYUNO Y, MITOMA C, et al. Therapeutic agents with AHR inhibiting and NRF2 activating activity for managing chloracne[J]. Antioxidants (Basel), 2018, 7(7):90. doi:10.3390/antiox7070090.
[27]	PETIT R G, CANO A, ORTIZ A, et al. Psoriasis:from pathogenesis to pharmacological and nano-technological-basedtherapeutics[J]. Int J Mol Sci, 2021, 22(9):4983. doi:10.3390/ijms22094983.
[28]	MAN A M, ORASAN M S, HOTEIUC O A, et al. Inflammation and psoriasis:A comprehensive review[J]. Int J Mol Sci, 2023, 24(22):16095. doi:10.3390/ijms242216095.
[29]	DI MEGLIO P, DUARTE J H, AHLFORS H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions[J]. Immunity, 2014, 40(6):989-1001. doi:10.1016/j.immuni.2014.04.019.
[30]	BISSONNETTE R, STEIN G L, RUBENSTEIN D S, et al. Tapinarof in the treatment of psoriasis:A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent[J]. J Am Acad Dermatol, 2021, 84(4):1059-1067. doi:10.1177/12034754241239050.
[31]	LIN X, MENG X, LIN J. The role of aryl hydrocarbon receptor in the pathogenesis and treatment of psoriasis[J]. J Cutan Med Surg, 2024, 28(3):276-286. doi:10.1177/12034754241239050.
[32]	TIAN C, ZHANG G, XIA Z, et al. Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model[J]. Eur J Med Chem, 2022,231:114122. doi:10.1016/j.ejmech.2022.114122.
[33]	ZHANG G, XIA Z, TIAN C, et al. Discovery of 5-((1H-indazol-3-yl) methylene)-2-thioxoimidazolidin-4-one derivatives as a new class of AHR agonists with anti-psoriasis activity in a mouse model[J]. Bioorg Med Chem Lett, 2023,92:129383. doi:10.1016/j.bmcl.2023.129383.
[34]	SROKA-TOMASZEWSKA J, TRZECIAK M. Molecular mechanisms of atopic dermatitis pathogenesis[J]. Int J Mol Sci, 2021, 22(8):4130. doi:10.3390/ijms22084130.
[35]	FADADU R P, ABUABARA K, BALMES J R, et al. Air pollution and atopic dermatitis, from molecular mechanisms to population-level evidence:a review[J]. Int J Environ Res Public Health, 2023, 20(3):2526. doi:10.3390/ijerph20032526.
[36]	SMITS J, EDERVEEN T, RIKKEN G, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides[J]. J Invest Dermatol, 2020, 140(2):415-424. doi:10.1016/j.jid.2019.06.142.
[37]	PALLER A S, STEIN G L, SOUNG J, et al. Efficacy and patient-reported outcomes from a phase 2b,randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis[J]. J Am Acad Dermatol, 2021, 84(3):632-638. doi:10.1016/j.jaad.2020.05.135.
[38]	AHN Y M, SHIN S, JANG J H, et al. Bojungikgi-tang improves skin barrier function and immune response in atopic dermatitis mice fed a low aryl hydrocarbon receptor ligand diet[J]. Chin Med, 2023, 18(1):100. doi:10.1186/s13020-023-00806-9.
[39]	BANGASH Y, SALEEM A, AKHTAR M F, et al. Pterostilbene reduces the progression of atopic dermatitis via modulating inflammatory and oxidative stress biomarkers in mice[J]. Inflammopharmacology, 2023, 31(3):1289-1303. doi:10.1186/s13020-023-00806-9.
[40]	PENG G, TSUKAMOTO S, IKUTAMA R, et al. Human beta-defensin-3 attenuates atopic dermatitis-like inflammation through autophagy activation and the aryl hydrocarbon receptor signaling pathway[J]. J Clin Invest, 2022, 132(17):e156501. doi:10.1172/JCI156501.
[41]	PREDA-NAUMESCU A, AHMED H N, MAYO T T, et al. Hidradenitis suppurativa:pathogenesis,clinical presentation,epidemiology,and comorbid associations[J]. Int J Dermatol, 2021, 60(11):e449-e458. doi:10.1111/ijd.15579.
[42]	MORAN B, SWEENEY C M, HUGHES R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis,which is corrected by anti-TNF therapy[J]. J Invest Dermatol, 2017, 137(11):2389-2395. doi:10.1016/j.jid.2017.05.033.
[43]	DAJNOKI Z, SOMOGYI O, MEDGYESI B, et al. Primary alterations during the development of hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2022, 36(3):462-471. doi:10.1111/jdv.17779.
[44]	ROTHHAMMER V, QUINTANA F J. The aryl hydrocarbon receptor:an environmental sensor integrating immune responses in health and disease[J]. Nat Rev Immunol, 2019, 19(3):184-197. doi:10.1038/s41577-019-0125-8.
[45]	SZELEST M, WALCZAK K, PLECH T. A new insight into the potential role of tryptophan-derived AhR ligands in skin physiological and pathological processes[J]. Int J Mol Sci, 2021, 22(3):1104. doi:10.3390/ijms22031104.
[46]	HUNT A, QIAN V, OLDS H, et al. The current clinical trial landscape for hidradenitis suppurativa:A narrative review[J]. Dermatol Ther(Heidelb), 2023, 13(7):1391-1407. doi:10.1007/s13555-023-00935-x.

芳香烃受体在炎症性皮肤病中的研究进展

Progress of the aryl hydrocarbon receptor in inflammatory skin diseases

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 1

参考文献 46

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈晶晶, 农章嵩, 谭良源, 杨培培, 梁英业, 唐宏亮, 王开龙. 小胶质细胞极化在神经病理性疼痛中作用研究进展[J]. 天津医药, 2024, 52(9): 1000-1003.
[2]	高攀, 谢冰歆, 周赞东, 刘彤. 慢性肾脏病循环中FGF23对心房纤维化的促进作用[J]. 天津医药, 2024, 52(9): 917-923.
[3]	范慧慧, 任玉梅, 田新磊, 张凯, 李晓丽. 止咳平喘方对支气管哮喘小鼠气道炎症及TLR4/TRAF6/NF-κB通路的影响[J]. 天津医药, 2024, 52(9): 924-929.
[4]	贾维宁, 鲍亚玲, 雷慧, 殷晓宁. 夏枯草提取物对脓毒症小鼠炎症反应和腹腔巨噬细胞的影响[J]. 天津医药, 2024, 52(9): 930-935.
[5]	徐琼芳, 钟斐, 李子帅. 淫羊藿苷调节SDF-1/CXCR4信号通路对多囊卵巢综合征大鼠卵巢颗粒细胞凋亡的影响[J]. 天津医药, 2024, 52(7): 727-732.
[6]	吴波, 朱卓农, 郑丽娟, 陈俊如. 苦参碱对特应性皮炎炎症、氧化应激和伤口愈合的影响[J]. 天津医药, 2024, 52(6): 566-571.
[7]	袁满, 冯子瀚, 谢敏, 王柏军. 大黄素对骨关节炎模型小鼠痛觉行为的调节机制[J]. 天津医药, 2024, 52(6): 572-577.
[8]	蒋韬, 程红艳, 吴琼. 棕矢车菊素调节SDF-1α/CXCR4信号通路对妊娠糖尿病大鼠炎症反应的影响[J]. 天津医药, 2024, 52(6): 594-598.
[9]	霍晶辰, 王悦, 李华, 邱嵘, 苏景伟, 王卓凡, 杨洁. 系统免疫炎症指数对根治性放疗Ⅲ期肺鳞癌患者长期生存的预测价值[J]. 天津医药, 2024, 52(6): 634-638.
[10]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[11]	慕静然, 骆延, 梁璇, 徐陶, 曾俊伟, 刘晓红. 补体系统激活参与阿尔茨海默病的研究进展[J]. 天津医药, 2024, 52(6): 663-668.
[12]	陈惠刚, 池小锋, 封娣, 米娅莉. 黄芪甲苷抑制Fas/FasL信号通路减轻创伤性脑损伤大鼠神经功能缺损和神经元凋亡[J]. 天津医药, 2024, 52(5): 469-474.
[13]	韩正怡, 李锐, 陈齐, 王家友, 盛奎, 宋洁, 张野. 收肌管阻滞联合全麻对老年全膝关节置换术患者术后疼痛和认知功能的影响[J]. 天津医药, 2024, 52(5): 523-527.
[14]	吕梦娜, 李建斌, 吴锐. 自身炎症性疾病患者合并COVID-19严重程度的早期预测指标探讨[J]. 天津医药, 2024, 52(5): 528-531.
[15]	贾西瑞, 刘莉洁. 小胶质细胞在脓毒症相关性脑病中的作用及研究进展[J]. 天津医药, 2024, 52(5): 557-560.